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Limited by what is reported in the literature, most
systematic reviews of medical tests focus on “test
accuracy” (or better, test performance), rather than on
the impact of testing on patient outcomes. The link
between testing, test results and patient outcomes is
typically complex: even when testing has high accuracy,
there is no guarantee that physicians will act according
to test results, that patients will follow their orders, or
that the intervention will yield a beneficial endpoint.
Therefore, test performance is typically not sufficient for
assessing the usefulness of medical tests. Modeling (in
the form of decision or economic analysis) is a natural
framework for linking test performance data to clinical
outcomes. We propose that (some) modeling should be
considered to facilitate the interpretation of summary
test performance measures by connecting testing and
patient outcomes. We discuss a simple algorithm for
helping systematic reviewers think through this possi-
bility, and illustrate it by means of an example.
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INTRODUCTION
This manuscript is part of a series of papers on mitigating
challenges encountered when performing systematic reviews of
medical tests, written by researchers participating in the
Agency for Healthcare Research and Quality (AHRQ) Effec-
tive Healthcare Program. Because most of these challenges are
generic, the series of papers in this supplement of the Journal
will probably be of interest to the wider audience of those who
perform or use systematic reviews of medical tests.
In the current paper we focus on modeling as an aid to
understand and interpret the results of systematic reviews of
medical tests. Limited by what is reported in the literature,
most systematic reviews focus on “test accuracy” (or better,
test performance), rather than on the impact of testing on
patient outcomes.1,2 The link between testing, test results and
patient outcomes is typically complex: even when testing has
high accuracy, there is no guarantee that physicians will act
according to tests results, that patients will follow their
orders, or that the intervention will yield a beneficial
endpoint.2 Therefore, test performance is typically not
sufficient for assessing the usefulness of medical tests.
Instead, one should compare complete test-and-treat strate-
gies (for which test performance is but a surrogate), but such
studies are very rare. Most often, evidence on diagnostic
performance, effectiveness and safety of interventions and
testing, patient adherence, and costs is available from
different studies. Much like the pieces of a puzzle, these
pieces of evidence should be put together to better interpret
and contextualize the results of a systematic review of
medical tests.1,2 Modeling (in the form of decision or
economic analysis) is a natural framework for performing
such calculations for test-and-treat strategies. It can link
together evidence from different sources; explore the impact
of uncertainty; make implicit assumptions clear; evaluate
tradeoffs in benefits, harms and costs; compare multiple test-
and-treat strategies that have never been compared head-to-
head; and explore hypothetical scenarios (e.g., assume
hypothetical interventions for incurable diseases).
This paper focuses on modeling for enhancing the
interpretation of systematic reviews of medical test accuracy,
and does not deal with the much more general use of
modeling as a framework for exploring complex decision
problems. Specifically, modeling that informs broader deci-
sionmaking may not fall in the purview of a systematic
review. Whether or not to perform modeling for informing
decisionmaking is often up to the decisionmakers themselves
(e.g., policy makers, clinicians, or guideline developers), who
would actually have to be receptive and appreciative of its
usefulness.3 Here we are primarily concerned with a
narrower use of modeling, namely to facilitate the interpre-
tation of summary test performance measures by connecting
the link between testing and patient outcomes. This decision
is in the purview of those planning and performing the
systematic review. In all likelihood, it would be impractical
to develop elaborate simulation models from scratch merely
to enhance the interpretation of a systematic review of
medical tests, but simpler models (be they decision trees or
even Markov process-based simulations) are feasible even in
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a short time span and with limited resources.3–5 Finally, how
to evaluate models is discussed in guidelines for good
modeling practices,6–13 but not here.
Undertaking a modeling exercise requires technical exper-
tise, good appreciation of clinical issues, and (sometimes
extensive) resources, and should be pursued when it is
informative. So when is it reasonable to perform decision or
cost effectiveness analyses to complement a systematic
review of medical tests? We provide practical suggestions
in the form of a stepwise algorithm.
A WORKABLE ALGORITHM
Table 1 outlines a practical 5-step approach that systematic
reviewers could use to decide whether modeling could be
used for interpreting and contextualizing the findings of a
systematic review of test performance, within time and
resource constraints. We outline these steps in an illustrative
example at the end of the paper.
Step 1. Define How the Test Will Be Used
The PICOTS typology (Population, Intervention, Comparators,
Outcomes, Timing, Study design) is a widely adopted
formalism for establishing the context of a systematic review.14
It clarifies the setting of interest (whether the test will be used
for screening, diagnosis, treatment guidance, patient monitor-
ing, or prognosis) and the intended role of the medical test
(whether it is the only test, an add-on to previously applied
tests, or for deciding on further diagnostic workups). The
information conveyed by the PICOTS items is crucial not only
for the systematic review, but for planning a meaningful
decision analysis as well.
Step 2. Use a Framework to Identify
Consequences of Testing
as well as Management Strategies
for Each Test Result
Medical tests exert most of their effects in an indirect way.
Notwithstanding the emotional, cognitive, and behavioral
changes induced by testing and its results,15 an accurate
diagnosis in itself is not expected to affect patient-relevant
outcomes. Nor do changes in test performance automatically
result in changes in any patient-relevant outcome. From this
point of view, test performance (as conveyed by sensitivity,
specificity, positive and negative likelihood ratios, or other
metrics) is only a surrogate end point. For example, testing
for human immunodeficiency virus has both direct and
indirect effects. The direct effects could include, but are not
limited to, potential emotional distress attributable to the
mere process of testing (irrespective of its results); the
cognitive and emotional benefits of knowing ones carrier
status (for accurate results); perhaps the (very rare) unneces-
sary stress caused by a false positive diagnosis; or possible
behavioral changes secondary to testing or its results. Indirect
effects include all the downstream effects of treatment
choices guided by the test results, such as benefits and
harms of treatment in true positive diagnoses, avoidance of
harms of treatment in true negative diagnoses, and cognitive
and behavioral changes.
Identifying the consequences of testing and its results is a
sine-qua-non for contextualizing and interpreting a medical
test’s (summary) sensitivity, specificity, and other measures
of performance. A reasonable start is the analytic frame-
work that was used to perform the systematic review (see
reference14). This can inform a basic tree illustrating test
consequences and management options that depend on test
results. This exercise helps the reviewers make explicit the
clinical scenarios of interest, the alternate (comparator)
strategies, and the assumptions made by the reviewers
regarding the test-and-treat strategies at hand.
Step 3. Assess Whether Modeling
May Be Useful
In most cases of evaluating medical testing, some type of
formal modeling will be useful. This is because of the
indirectness of the link between testing and health out-
comes, and the multitude of test-and-treat strategies that can
be reasonably contrasted. Therefore, it may be easier to
examine the opposite question (i.e., when formal modeling
may not be necessary or useful). We briefly explore two
general cases. In the first, one of the test-and-treat strategies
is clearly superior to all alternate strategies. In the second,
information is too scarce regarding which modeling
assumptions are reasonable, what the downstream effects
of testing are, or what are plausible values of multiple
central (influential) parameters.
The Case Where a Test-and-Treat Strategy is a “Clear
Winner”. A comprehensive discussion of this case is provided
by Lord et al.16,17 For some medical testing evaluations, one
can identify a clearly superior test-and-treat strategy without
any need for modeling. The most straightforward case is
Table 1. Proposed Algorithm to Decide if Modeling Should be a
Part of the Systematic Review
Step Description
1 Define how the test will be used
2 Use a framework to identify consequences of testing as well
as management strategies for each test result
3 Assess if modeling is useful
4 Evaluate prior modeling studies
5 Consider whether modeling is practically feasible in time
frame given
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when there is direct comparative evidence for all the test-and-
treat strategies of interest. Such evidence could be obtained
from well-designed, -conducted and -analyzed randomized
trials, or even nonrandomized studies. Insofar as these studies
are applicable to the clinical context of interest in the patient
population of interest, evaluate all important test-and-treat
strategies, and identify a dominant strategy with respect to both
benefits and harms and with adequate power, modeling may
be superfluous. In all fairness, direct comparative evidence for
all test-and-treat strategies of interest is exceedingly rare.
In the absence of direct comparisons of complete test-and-
treat strategies, one can rely on test accuracy only, as long as
it is known that the patients who are selected for treatment
using different tests will have the same response to
downstream treatments. Although the downstream treatments
may be the same in all test-and-treat strategies of interest, one
cannot automatically deduce that patients selected with
different tests will exhibit similar treatment response.2,14,16,17
Estimates of treatment effectiveness on patients selected with
one test do not necessarily generalize to patients selected
with another test. For example, the effectiveness of treatment
for women with early-stage breast cancer is primarily based
on cases diagnosed with mammography. Magnetic resonance
imaging (MRI) can diagnose additional cases, but it is at best
unclear whether these additional cases have the same
treatment response.18 We will return to this point soon.
If it were known that patient groups identified with different
tests respond to treatment in the same way, one could select
the most preferable test (test-and-treat strategy) based on
considerations of test characteristics alone. Essentially, one
would evaluate three categories of attributes: the cost and
safety of testing; the sensitivity of the tests (ability to
correctly identify those with the disease, and thus to proceed
to hopefully beneficial interventions); and the specificity of
the tests (ability to correctly identify those without disease,
and thus avoid the harms and costs of unnecessary
treatment). A test-and-treat strategy would be universally
dominant if it were preferable versus all alternative strategies
and over all three categories of attributes. In case of tradeoffs,
i.e., one test has better specificity but another one is safer
(with all other attributes being equal), one would have to
explore these tradeoffs using modeling.
So how does one infer whether patient groups identified
with different tests have (or should have) the same response
to treatment? Several cases may be described. First,
randomized trials may exist suggesting that the treatment
effects are similar in patients identified with different tests.
For example, the effect of stenting versus angioplasty on
reinfarctions in patients with acute myocardial infarction
does not appear to differ by the test combinations used to
identify the included patients.19 Thus, when comparing
various tests for diagnosing acute coronary events in the
emergency department setting, test performance alone is
probably a good surrogate for the clinical outcomes of the
complete test-and-treat strategies. In the absence of direct
empirical information from trials, one could use judgment to
infer whether the cases detected from different tests would
have a similar response to treatment. Lord et al. propose that
when the sensitivity of two tests is very similar, it is often
reasonable to expect that the “case mix” of the patients who
will be selected for treatment based on test results will be
similar, and thus patients would respond to treatment in a
similar way.16,17 For example, Doppler ultrasonography and
venography have similar sensitivity and specificity to detect
the treatable condition of symptomatic distal deep venous
thrombosis.20 Because Doppler is easier, faster, and non-
invasive, it is the preferable test.
When the sensitivities of the compared tests are different, it
is more likely that the additional cases detected by the more
sensitive tests may not have the same treatment response. In
most cases this will not be known, and thus modeling would
be useful to explore the impact of potential differential
treatment response on outcomes. Sometimes we can reason-
ably extrapolate that treatment effectiveness will be unaltered
in the additional identified cases. This is when the tests
operate on the same principle, and the clinical and biological
characteristics of the additional identified cases are expected
to remain unaltered. An example is computed tomography
(CT) colonography for detection of large polyps, with
positive cases subjected to colonoscopy as a confirmatory
test. Dual positioning (prone and supine) of patients during
the CT is more sensitive than supine-only positioning,
without differences in specificity.21 It is very reasonable to
expect that the additional cases detected by dual positioning
in CT will respond to treatment in the same way as the cases
detected by supine-only positioning, especially since colono-
scopy is a universal confirmatory test.
The Case of Very Scarce Information. There are times
when we lack an understanding of the underlying disease
processes to such an extent that we are unable to develop a
credible model to estimate outcomes. In such circumstances,
modeling is not expected to enhance the interpretation of a
systematic review of test accuracy, and thus should not be
performed with this goal in mind. This is a distinction
between the narrow use of modeling we explore here (to
contextualize the findings of a systematic review) and its
more general use for decisionmaking purposes. Arguably, in
the general case, modeling is especially helpful, because it is
a disciplined and theoretically motivated way to explore
alternative choices. In addition, it can help identify the major
factors that contribute to the uncertainty, as is done in value
of information analyses.22,23
Step 4. Evaluate Prior Modeling Studies
Prior to developing a model de novo or adapting an existing
model, one should consider searching the literature to ensure
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that the modeling has not already been done. There are several
considerations when evaluating previous modeling studies.
First, one has to judge the quality of the models. Several
groups have made recommendations on evaluating the quality
of modeling studies, especially in the context of cost-
effectiveness analyses.6,8–13 Evaluating the quality of a model
is a very challenging task. More advanced modeling can be
less transparent and difficult to describe in full technical detail.
Increased flexibility often has its toll: Essential quantities may
be completely unknown (“deep” parameters) and must be set
through assumptions or by calibrating model predictions
versus real empirical data.24 MISCAN-COLON25,26 and
SimCRC27 are two microsimulation models describing the
natural history of colorectal cancer. Both assume an adenoma-
carcinoma sequence for cancer development but differ in their
assumptions on adenoma growth rates. Tumor dwell time (an
unknown deep parameter in both models) was set to
approximately 10 years in MISCAN-COLON;26,28 and to
approximately 30 years in SimCRC. Because of such differ-
ences, models can reach different conclusions.29 Ideally,
simulation models should be validated against independent
datasets that are comparable to the datasets on which the
models were developed.24 External validation is particularly
important for simulation models in which the unobserved
deep parameters are set without calibration (based on
assumptions and analytical calculations).24,25
Second, once the systematic reviewers deem that good
quality models exist, they have to examine whether the
models are applicable to the interventions and populations
of the current evaluation; i.e., if they match the PICOTS
items of the systematic review. In addition, the reviewers
have to judge whether methodological and epidemiological
challenges have been adequately addressed by the model
developers.2
Third, the reviewers have to explore the applicability of
the underlying parameters of the models. Most importantly,
preexisting models will not have had the benefit of the
current systematic review to estimate diagnostic accuracy,
and they may have used estimates that differ from the ones
obtained by the systematic review. Also, consideration
should be given to whether our knowledge of the natural
history of disease has changed since publication of the
modeling study (thus potentially affecting parameters in the
underlying disease model).
If other modeling papers meet these three challenges, then
synthesizing the existing modeling literature may suffice.
Alternatively, developing a new model may be considered, or
one could explore the possibility of cooperating with
developers of existing high quality models to address the
key questions of interest. The US Preventive Services Task
Force and the Technology Assessment program of AHRQ
have followed this practice for specific topics. For example,
the USPSTF recommendations for colonoscopy screening30
were informed by simulations based on the aforementioned
MISCAN-COLON and SimCRC microsimulation models,27,31
which were developed outside the EPC program.25,26
Step 5. Consider Whether Modeling
is Practically Feasible in the Given
Time Frame
Even if modeling is determined to be useful, it may still
not be feasible to develop an adequately robust model
within the context of a systematic review. Time and
budgetary constraints, lack of experienced personnel, and
other needs may all play a role in limiting the feasibility of
developing or adapting a model to answer the relevant
questions. Even if a robust and relevant model has been
published, it is not necessarily accessible. Models are often
considered intellectual property of their developers or
institutions, and they may not be unconditionally available
for a variety of reasons. Further, even if a preexisting
model is available, it may not be sufficient to address the
key questions without extensive modifications by experi-
enced and technically adept researchers. Additional data
may be necessary, but they may not be available. Of
importance, the literature required for developing or adapting
a model does not necessarily overlap with that used for an
evidence report.
Further, it may also be the case that the direction of the
modeling project changes based on insights gained during the
conduct of the systematic review or during the development
of the model. Although this challenge can be mitigated by
careful planning, it is not entirely avoidable.
If the systematic reviewers determine that a model would be
useful but not feasible within the context of the systematic
review, consideration should be given to whether these efforts
could be done sequentially as related but distinct projects. The
systematic review could synthesize available evidence,
identify gaps, and estimate many necessary parameters for a
model. The systematic review can also call for the develop-
ment of a model in the future research recommendations
section. A subsequent report that uses modeling could inform
on long-term outcomes.
ILLUSTRATION
Here, we illustrate how the aforementioned algorithm could
be applied using an example of a systematic review of
medical tests in which modeling was deemed important to
contextualize findings on test performance.32 Specifically, we
discuss how the algorithm could be used to determine if a
model is necessary for an evidence report on the ability of
positron emission tomography (PET) to guide the manage-
ment of suspected Alzheimer’s disease (AD), a progressive
neurodegenerative disease for which current treatment options
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are at best modestly effective.32 The report addressed three
key questions, expressed as three clinical scenarios:
1. Scenario A: In patients with dementia, can PET be used
to determine the type of dementia that would facilitate
early treatment of AD and perhaps other dementia
subtypes?
2. Scenario B: For patients with mild cognitive impairment,
could PET be used to identify a group of patients with a
high probability of AD so that they could start early
treatment?
3. Scenario C: Is the available evidence enough to justify the
use of PET to identify a group of patients with a family
history of AD so that they could start early treatment?
The systematic review of the literature provides summaries
of the diagnostic performance of PET to identify AD, but
does not include longitudinal studies or randomized trials on
the effects of PET testing on disease progression, mortality or
other clinical outcomes. In the absense of direct comparative
data for the complete test-and-treat strategies of interest,
decision modeling may be needed to link test results to long
term patient-relevant outcomes.
Step 1: Define How PET Will Be Used
The complete PICOTS specification for the PET example is
described in the evidence report32 and is not reviewed here
in detail. In brief, the report focuses on the diagnosis of the
disease (AD) in the three scenarios of patients with
suggestive symptoms. AD is typically diagnosed with a
clinical exam that includes complete history, physical and
neuropsychiatric evaluation, and screening laboratory test-
ing.33 In all three scenarios, we are only interested in PET as a
“confirmatory” test ( i.e., we are only interested in PET added
upon the usual diagnostic workup). Specifically, we assume
that PET (1) is used for diagnosing patients with different
severities or types of AD (mild or moderate AD, mild
cognitive impairment, family history of AD), (2) it is an add-
on to a clinical exam, and (3) should be compared against the
clinical exam (i.e. no PET as an add-on test). We are explicitly
not evaluating patient management strategies where PET is the
only test (i.e., PET “replaces” the typical exam) or where it
triages who will receive the clinical exam (an unrealistic
scenario). Table 2 classifies the results of PET testing.
Step 2: Create a Simplified Analytic
Framework and Outline How Patient
Management Will Be Affected by Test Results
The PET evidence report does not document any apprecia-
ble direct effects or complications of testing with or without
PET. Thus, it would be reasonable to consider all direct
effects of testing as negligible when interpreting the results
of the systematic review of test performance. A simplified
analytic framework is depicted in Figure 1, and represents
the systematic reviewers’ understanding of the setting of the
test, and its role in the test-and-treat strategies of interest.
The analytic framework also outlines the reviewers’
understanding regarding the anticipated effects of PET
testing on mortality and disease progression: any effects
are only indirect, and exclusively conferred through the
downstream clinical decision of whether to treat patients. In
the clinical scenarios of interest, patients with a positive test
result (either by clinical exam or by the clinical exam-PET
combination) will receive treatment. However, only those
with AD (true positives) would benefit from treatment.
Those who are falsely positive would receive no benefit but
will still be exposed to the risk of treatment-related adverse
effects, and the accompanying polypharmacy. (By design, the
evidence report on which this illustration is based did not
address costs, and thus we make no mention of costs here.)
Figure 2 shows an outline of the management options in
the form of a simple tree, for the clinical scenario of people
with mild cognitive impairment (MCI) in the initial clinical
exam (scenario B above). Similar basic trees can be
constructed for the other clinical scenarios. The aim of this
figure is to outline the management options for positive and
negative tests (here they are simple: receive treatment or
not) and the important consequences of being classified as a
true positive, true negative, false positive or false negative,
as well as to make explicit the compared test-and-treat
strategies. This simplified outline is a bird’s-eye-view of a
decision tree for the specific clinical test.
Step 3: Assessing Whether Modeling
Could Be Useful in the PET and AD Evidence
Report
In the example, no test-and-treat strategies have been
compared head-to-head in clinical studies. Evidence exists
to estimate the benefits and harms of pharmacologic therapy
in those with and without AD. Specifically, the treatments for
MCI in AD are at best only marginally effective,32 and it is
unknown whether subgroups of patients identified by PET
may have differential responses to treatment. Hence, we
Table 2. Crosstabulation of PET Results and Actual Clinical
Status Among Patients with Initial Clinical Examination
Suggestive of Alzheimer’s
AD in long term
clinical evaluation




“True positive” “False positive”
PET not suggestive
of AD
“False negative” “True negative”
AD: Alzheimer’s disease; PET: positron emission tomography.
Counts in this table correspond to patients with an initial clinical
examination suggestive of AD (as defined in the three clinical
scenarios). Patients without suggestive clinical examination are not
candidates for PET testing
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cannot identify a “clear winner” based on test performance
data alone, and modeling was deemed useful.
Step 4: Assessing Whether Prior Modeling
Studies Could Be Utilized
In this particular example, the systematic reviewers per-
formed decision modeling. Apart from using the model to
better contextualize their findings, they also explored
whether their conclusions would differ if the treatment
options were more effective than the options currently
available. The exploration of such “what if” scenarios can
inform the robustness of the conclusions of the systematic
review, and can also be a useful aid in communicating
conclusions to decisionmakers. It is not stated whether the
systematic reviewers searched for prior modeling studies in
the actual example. Although we do not know of
specialized hedges to identify modeling studies, we suspect
that even simple searches using terms such as “model(s)”,
“modeling”, “simulat*”, or terms for decision or economic
analysis would suffice.
Step 5. Consider Whether Modeling
is Practically Feasible in the Time Frame
Given
Obviously modeling was deemed feasible in the example at
hand.
Figure 1. Simplified analytic framework. AD: Alzheimer’s disease; AChE-I: acetylcholinesterase inhibitors (the treatment available at the
time of the evidence report). The framework assumes no major adverse effects from the treatment.
Figure 2. Management options for mild cognitive impairment. * When applicable. As per the evidence report, the then-available treatment
options (achetylcholinesterase inhibitors) do not have important adverse effects. However, in other cases, harms can be induced both by the
treatment and the test (e.g., if the test is invasive). The evidence report also modeled hypothetical treatments with various effectiveness and
safety profiles to gain insight on how sensitive their conclusions were to treatment characteristics. Note that at the time the evidence report
was performed, other testing options for Alzheimer’s were not in consideration. AD: Alzheimer’s disease; MCI: mild cognitive impairment;
PET: positron emission tomography.
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OVERALL SUGGESTIONS
& Many systematic reviews of medical tests focus on test
performance, rather than the clinical utility of a test.
Systematic reviewers should explore whether modeling
may be helpful in enhancing the interpretation of test
performance data and obtaining insight into the dynamic
interplay of various factors on decision-relevant effects.
& The five-step algorithm of Table 1 can help evaluate
whether modeling is appropriate for the interpretation of
a systematic review of medical tests.
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